<- Go Home
Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Market Cap
AUD 656.1M
Volume
20.3K
Cash and Equivalents
AUD 282.7M
EBITDA
-AUD 94.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 1.4M
Profit Margin
74.28%
52 Week High
AUD 7.11
52 Week Low
AUD 3.40
Dividend
N/A
Price / Book Value
2.35
Price / Earnings
-3.44
Price / Tangible Book Value
2.35
Enterprise Value
AUD 377.1M
Enterprise Value / EBITDA
-4.03
Operating Income
-AUD 96.1M
Return on Equity
59.21%
Return on Assets
-33.99
Cash and Short Term Investments
AUD 282.7M
Debt
AUD 3.7M
Equity
AUD 278.4M
Revenue
AUD 1.9M
Unlevered FCF
-AUD 52.6M
Sector
Health Care Equipment and Supplies
Category
N/A